Piramal Pharma Ltd announced its unaudited financial results for Q2 and H1 FY26, reporting total revenues of 2,044 crores and a net loss of 99 crores for Q2; revenues decreased by 9% YoY due to customer inventory destocking in a large CDMO order. The company highlighted a reduced net debt of 3,971 crores and a focus on sustainability with the release of their 4th Annual Sustainability Report.